Similar Articles |
|
The Motley Fool December 18, 2009 Brian Orelli |
Swine Flu Just Isn't Bringing Home the Bacon Looks like that one-time boost from sales of swine flu vaccine may not add much to the bottom lines of vaccine makers like GlaxoSmithKline, AstraZeneca, sanofi-aventis, and Novartis. |
The Motley Fool February 23, 2010 Brian Orelli |
The End of a Swine Flu Era A Food and Drug Administration advisory panel recommended yesterday that next year's seasonal flu vaccine contain the vaccine for the H1N1 virus, aka the swine flu. |
The Motley Fool September 16, 2009 Brian Orelli |
Here Come the Swine Flu Vaccines Drugmakers moved one step closer to getting swine flu vaccines into your arm with approvals by the Food and Drug Administration. |
The Motley Fool June 12, 2009 Brian Orelli |
Be Careful What You Wish For Do you have the stomach to profit from swine flu? |
The Motley Fool October 17, 2005 Brian Gorman |
Chasing Down Bird Flu Sanofi and GlaxoSmithKline are emerging as the likely winners in the race to produce a bird flu vaccine. |
The Motley Fool February 4, 2010 Brian Orelli |
Glaxo Brings Home the Bacon Swine flu gives GlaxoSmithKline the boost, but how long will it last? |
BusinessWeek January 9, 2006 Carol Matlack |
Preventing The Pandemic France's Sanofi Pasteur is already signing contracts for an avian flu vaccine. |
The Motley Fool April 27, 2009 Brian Orelli |
A Capitalist Pig's View of Swine Flu So you want to make money from the swine flu? Here's how to do so. |
The Motley Fool September 2, 2005 Rich Duprey |
Will Flu Vaccine Catch Cold? The CDC says we may have as many as 97 million doses this year, but that's a best-case scenario. This year again, it's Chiron causing the uncertainty. |
The Motley Fool March 16, 2006 Rich Duprey |
Avian Flu Ruffling Feathers Roche Pharmaceuticals boosts anti-flu drug production to quiet calls for generics. While the situation bears watching for now, it's not necessarily something for investors to get their feathers ruffled about. |
The Motley Fool September 7, 2005 Rich Duprey |
Is Chiron Worth It? The vaccine maker rejects Novartis' bid of $40 a share as inadequate. How much should the pharma pay? Investors, take note. |
The Motley Fool January 12, 2010 Brian Orelli |
Swine Flu: The Side Dish That Couldn't Last More governments canceling vaccine-purchasing contracts. The sky is falling on swine-flu-vaccine makers. |
The Motley Fool October 18, 2005 Rich Duprey |
Chiron's Sickly Forecast The flu vaccine maker further reduces its estimated dose production. With its earnings release due next week, perhaps Chiron was simply preparing investors for a jolt. |
The Motley Fool March 1, 2011 Brian Orelli |
Uncle Sam Gives Novavax a Big Hand Up Cash is everything for a development-stage drugmaker. |
The Motley Fool August 21, 2009 Brian Orelli |
Forget Swine Flu: The Big Money Is Here Vaccines are pharma's, and possibly investors', best friend. |
The Motley Fool October 14, 2005 Rich Duprey |
Chiron Ready to Fly Flu vaccine maker readies first shipments as flu season begins and avian flu fears rise. |
The Motley Fool May 28, 2009 Brian Orelli |
How to Make a Stockpile in Your Portfolio The swine flu has turned out to be a relative dud, hasn't it? It hasn't done much but create a buying opportunity for those who didn't panic. Where should you look to profit from it now? |
The Motley Fool May 27, 2005 Rich Duprey |
Glaxo's Flu Vaccine Booster The drug giant's return could give the U.S. flu vaccine market a shot in the arm. |
The Motley Fool October 31, 2005 Rich Duprey |
Chiron Not Immune to Merger The board accepts a sweetened buyout offer from Swiss pharmaceutical firm Novartis. Investors, take note. |
AskMen.com Jacob Franek |
Swine Flu Update With the fall flu season rapidly approaching, a swine flu update is warranted. |
The Motley Fool April 29, 2010 Brian Orelli |
Earnings Up 17%, but Here's Why You Should Be Worried One-time sales are no way to run a pharmaceutical business. |
The Motley Fool October 28, 2005 Rich Duprey |
Chiron's Bird Flu Contract As Asian bird flu becomes the crisis du jour, this flu vaccine biotech is awarded a hefty contract. |
Pharmaceutical Executive December 1, 2005 Anthony Tao |
The Avian Few: Is it Too Late for Pharma to Re-enter the Vaccine Fray? Small profit margins and high litigation risks drove most companies out of the vaccine business decades ago. As a possible pandemic looms, pharma re-enters the fray. Is it too late? |
BusinessWeek February 4, 2010 Weintraub et al. |
Swine Flu: The Pandemic That Wasn't Swine flu is waning, but the lessons of H1N1 could come in handy during a more serious epidemic. |
Chemistry World December 15, 2009 Sarah Houlton |
Pharma's year of merger mania Away from the corporate world, the big pharma story of 2009 was the emergence of a new health scare - swine flu. |
AskMen.com |
Drug-Resistant Swine Flu Surfaces Health officials have confirmed a case of swine flu that is resistant to Tamiflu, the leading pharmaceutical weapon against the new virus. |
Chemistry World February 2006 |
Editorial: Fighting Avian Flu Participants at a world avian flu conference in Beijing committed to increasing cooperation on global vaccine and anti-viral research and development. |
The Motley Fool October 6, 2004 Rich Duprey |
Chiron Sneezes, Investors Catch Cold British authorities shut down the pharmaceutical's only U.S. flu vaccine manufacturing facility. This may in fact be an opportunity to scoop up a beleaguered stock at fire sale prices. |
The Motley Fool November 30, 2006 Brian Lawler |
Happy (Sniffle) Holidays (Cough) It's flu season again, and the market for influenza vaccines is hot. Pharma investors, take note. |
BusinessWeek October 24, 2005 John Carey |
New Vaccines For A Pandemic Using DNA, vast amounts of flu vaccine could be made quickly. But will the drugs work? |
American Family Physician January 15, 2004 |
Influenza Vaccine What is influenza?... Who is at higher risk?... What is the flu vaccine?... Is the vaccine safe?... etc. |
The Motley Fool December 13, 2011 Frank Vinluan |
N.C. Novartis Site Is First Cell-Based Flu Vaccine Facility in the Country A Novartis' vaccine facility in North Carolina today became the first facility authorized by the FDA for emergency use during a pandemic. |
AskMen.com |
1 Million Swine Flu Cases? Swine flu has infected as many as 1 million Americans, U.S. health officials said Thursday, adding that 6 percent or more of some urban populations are infected. |
The Motley Fool March 3, 2005 Rich Duprey |
Chiron Back From the Dead British authorities give vaccine manufacturer the go-ahead to restart facility. Investors can breathe a sigh of relief. |
The Motley Fool July 5, 2006 Rich Duprey |
Flu Vaccine Deja Vu The country's largest vaccine maker, Sanofi Aventis, gets an FDA warning letter reminiscent of the 2004 debacle. |
Health October 2007 Sarah Clachar |
Read this BEFORE you get a flu shot The flu vaccine may not be as good -- or as safe -- as you think. |
The Motley Fool July 29, 2009 Brian Orelli |
The Swine Flu Can't Save Sanofi No shocker there. |
The Motley Fool March 30, 2006 David Compton |
Glaxo's New Flu-Fighting Ammo The FDA certifies the drugmaker's Relenza for defense as well as offense. For investors seeking to give their portfolios a shot in the arm, now might be the time to take a closer look at Glaxo. |
The Motley Fool October 26, 2011 Chris Baines |
Why Getting A Flu Shot Is Critical Vaccines save the lives of millions. By getting a flu shot, you're also aiding future vaccine research conducted by major pharmaceutical companies. |
Chemistry World January 22, 2013 Andrew Turley |
Flu vaccine without the eggs approved Flublok from US biotech Protein Sciences has become the first flu vaccine made using an insect virus to win marketing approval in the US. |
The Motley Fool October 28, 2009 Brian Orelli |
Saved by Emerging Markets. Sort Of. GlaxoSmithKline's top line looks good, but the bottom is what counts. |
The Motley Fool January 27, 2010 Brian Orelli |
Nice, Novartis, Very Nice CEO Daniel Vasella leaves on a high note. |
American Family Physician October 1, 2004 |
Flu Vaccinations A general overview on what flu vaccines are and how they can help. |
The Motley Fool October 19, 2004 Rich Duprey |
Chiron Crisis Creates Investor Opportunity As flu vaccine maker flames out, other companies may step in to fill the void. |
The Motley Fool January 26, 2005 Rich Duprey |
Chiron's Earnings Ills Flu vaccine manufacturer expected to report significantly lower profits. |
AskMen.com Jacob Franek |
Swine Flu: The Good, The Bad And The Ugly Here is a short list of what we do and don't know of swine flu. |
Chemistry World April 25, 2014 Andy Extance |
$25bn-plus trade sharpens pharma giants' focus Three leading pharmaceutical firms are set to exchange business segments valued at over $25 billion, in deals affecting at least 14,000 employees. |
The Motley Fool June 15, 2007 Brian Orelli |
Get Your Uncle to Pay for Your Capital Improvements MedImmune and Sanofi-Aventis recently announced that they had convinced the U.S. government to pick up a majority of the tabs to renovate their plants. There aren't too many industries where you can invest in companies that get free money from the government. |
The Motley Fool August 20, 2007 Brian Orelli |
Contracts That Are for the Birds Baxter and GlaxoSmithKline get bird flu vaccine contracts from the U.K. These contracts aren't reasons by themselves to run out and buy the companies' stock, but expanding income sources are almost always a good sign. |
Pharmaceutical Executive May 1, 2006 Pasternak et al. |
Vaccines: Market on the Rebound The vaccine business was safely inoculated against higher profits. But innovative therapies and looser government controls may spark an outbreak. Are pharmaceuticals ready for this opportunity? |